EP0191221A1 - Vektoren zur Transformation von Ascomyceten - Google Patents

Vektoren zur Transformation von Ascomyceten Download PDF

Info

Publication number
EP0191221A1
EP0191221A1 EP85307648A EP85307648A EP0191221A1 EP 0191221 A1 EP0191221 A1 EP 0191221A1 EP 85307648 A EP85307648 A EP 85307648A EP 85307648 A EP85307648 A EP 85307648A EP 0191221 A1 EP0191221 A1 EP 0191221A1
Authority
EP
European Patent Office
Prior art keywords
vector
ascomycete
gene
host
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP85307648A
Other languages
English (en)
French (fr)
Inventor
William E. Timberlake
John E. Hamer
M. Melanie Yelton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP0191221A1 publication Critical patent/EP0191221A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03002—Laccase (1.10.3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0061—Laccase (1.10.3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Definitions

  • the invention relates to the recombinant manipulation of a fungal subclass, the filamentous ascomycetes.
  • the invention relates to vectors, control sequences, and procedures for utilization of various filamentous ascomycete species as transformant hosts and as cellular laboratories for genetic manipulation.
  • the ascomycetes comprise a class of fungi which includes among its members a number of useful, familiar, and important eucaryotic organisms. Perhaps the best known among these are the yeast strains which are familiar to all in connection with production of alcoholic beverages and of bakery goods. Other well known representatives include Neuros p ora crassa which is most frequently encountered as a pinkish bread mold, the ringworm which accounts for a formerly more common skin disease, and the blue molds which account for the flavor and appearance ofdian and Roquefort cheese.
  • the ascomycetes occur in two significantly distinctive types: those which form a filamentous mycelium, the "euascomycetes” and those which do not, the "hemiascomycetes".
  • One authoritative taxonomy of the ascomycetes (never a static classification, however) sets forth five subclasses, four of which are of the first subtype, and one of which is of the second. (Alexopolous, C. et al, Introductory Mycology (J. Wiley and Sons, N.Y.).
  • the subclass hemiascomycetidae which is of the second type, includes the yeasts such as Saccharom y ces and Candida. Genetic manipulation of members of this subclass and methods for transformation thereof, have been relatively well developed (see, for example. Van Solingen. P., et al. J Bact (1977) 130:946).
  • the Tarining subclasses two contain organisms of industrial importance: the Plectomycetidae which contains black molds, blue molds, and ringworms, including the various Aspergillus and Penicillium species: and the subclass Pyrenomycetes which is represented by the various organisms causing mildew and by N. crassa, and by strains of Trichoderma and of Cephalosporium.
  • Gene (19 ) 26:205 have transformed A nidulans with a plasmid carrying the asds A. nidulans gene.
  • this gene which is expressed to confer phenotypic characteristics including sensitivity to fluoroacetate and ability to grow on acetamide, has been found only in A. nidulans strains, and thus may find no indigenous counterparts in the remaining filamentous ascomycetes species.
  • the invention relates to systems for genetic manipulation of the filamentous ascomycetes. and to the methods and tools useful in these systems.
  • Vectors are provided that permit the transformation of the various strains of Asuergillus, and that serve as intermediate vectors for ascomycete expression in general. These vectors use DNA control sequences homologous to the host to regulate the expression of a selectable marker in suitable host strains.
  • cosmid vectors which permit the isolation, cloning, sequencing, and modification of genes from the filamentous ascomycetes. This permits the cosmids of the invention to be used as shuttles for genetic manipulation of the species or strain furnishing the gene, as well as for the purpose of obtaining large amounts of a desired ascomycete gene.
  • these cosmid vectors can be used to provide gene sequences from a spectrum of fungal species as sources of signal sequences for the secretion of proteins encoded by selected foreign DNA sequences linked in suitable reading frame.
  • This application is of considerable importance because, in contrast to the yeast representatives of the ascomycetes. the filamentous members are "natural" secreters, i.e.. proteins containing suitable signal sequences are expelled into the medium, rather than harbored in the periplasmic space as is the case with yeast.
  • vectors of the invention are useful as intermediates to desired expression vectors for heterologous proteins in ascomycete hosts, as well as serving as shuttles to enable generic modification of indigenous sequences.
  • the invention relates to an Aspergillus derived selectable marker for ascomycetes.
  • the invention also relates to control sequences therefor, and to vectors containing these control and marker sequences, along with sequences of bacterial origin.
  • the invention relates to cosmid vectors which comprise such selectable marker, along with these associated control sequences, bacterial shuttle sequences, and a unique restriction site suitably disposed to accept desired additional ascomycete genomic sequences.
  • the invention relates to recombinant hosts transformed with these vectors, and to DNA sequences, vectors, and most particularly to genes derived from these vectors.
  • the invention further relates to methods for obtaining genes from filamentous ascomycetes, for modifying such genes and for modifying the genome of filamentous ascomycetes.
  • a vector "derived from” another vector refers to a vector which contains DNA sequences or fragments thereof, which are obtained by utilizing the vector of origin suitably treated with restriction enzymes.
  • vectors derived from pHY201 are those which incorporate portions of DNA (or replications thereof) obtained from pHY201 by treatment with restriction enzymes. They also include vectors formed from DNA sequences rescued from chromosomal DNA of hosts transformed with the vector of origin, e.g.. pHY201 as described herein, which recovered DNA contains sequences corresponding to those of the original transforming vector.
  • the definition also includes sequences substantially similar to those of the parent vector, though not exactly identical. These might, for example, be obtained by replication of the originating vector sequences with slightly modified primers to effect site directed mutagenesis. or may arise fortuitously. However, such changes, in maintaining substantial similarity to the original sequence, will not materially alter functionality.
  • “Mutagenically derived from” refers to a subset of such vectors obtained by subjecting a host harboring the vector of origin to substances or conditions which cause mutations in the vector to give desired altered products.
  • One of the utilities of the vectors described herein depends on their suitablility as vectors of origin for such genetic manipulation, especially using bacterial or ascomycete hosts.
  • vectors "mutagenically derived” from those of the invention are the product vectors of this manipulation.
  • Control sequences refen to DNA sequences which are capable of directing and controlling the expression of an operably linked coding sequence in ascomycetes.
  • ascomycetes are eucaryotic cells, such sequences include, but are not limited to, promoters and terminators. It is understood that modifications of these sequences may be sufficiently innoccuous to modify the level of, but not to halt entirely, the expression of the coding sequence. Such modifications are also included within the definition of control sequences. (Some modifications may, in fact, enhance the relevant expression level.)
  • Cosmid vectors refers to vectors which contain the cos fragment, thus permitting them to be packaged into ⁇ phage.
  • the origins, and functionality of the cos site sequences are well known in the art.
  • cosmid vectors of the proper size i.e., approximately 45-50 kb
  • E. coli hosts. Phage replication in these transformed hosts results in a high copy number of the DNA comprising the cosmid.
  • Vector is used generically to include plasmids, cosmids, linear transforming DNA, or any other type of DNA sequence capable of transfecting a host. Where a specific type of vector is intended, this will be clear from the context.
  • Selectable marker refers to a DNA sequence which encodes a protein permitting the host organism expressing the sequence to survive on selective media.
  • “Integration at the homologous site” refers to replacement of a section of genomic DNA with foreign DNA which encodes the analogous protein.
  • homologous integration of the trpC + gene, as described herein occurs at the mutated site of the genome containing the modified sequence which would, in the wild type host, have encoded trpC.
  • the host organism In order for homologous recombination to occur, the host organism must have a sequence in its genome which is a modified form of the incoming DNA.
  • Genes derived from the cosmids of the inventions refers to genes which are prepared using the cosmids of the invention as intermediates in their preparation.
  • “Filamentous ascomycetes” refers to those ascomycetes which form a mycelium through a mass of branching, interlocking filaments which, although interrupted by cross walls, permit the passage of cytoplasm between compartments due to perforations in the walls.
  • the filaments thus contain a multiplicity of nuclei in a transportable cytoplasm.
  • Many of these fungi form meiotic spores within a sac when propagated sexually: however, upon proper stimulation, the mechanism of which is not entirely understood. reproduction functions asexually. In this manner of reproduction, condia are borne externally at the tips of budding projections formed at various locations along the filaments.
  • the filamentous ascomycetes which are the basis for the present invention are members of the two subclasses set forth above. As has been mentioned previously, there are two known additional subclasses. but the members of these subclasses are relatively rare as laboratory or industrial organisms, and may or may not be compatible with the techniques and vectors of the present invention. However, the filamentous ascomycetes are clearly differentiated morphologically from the hemiascomycetes, i.e. the yeast containing subclass.
  • Transformed when used herein in the context of transforming.a recombinant host, refers to any mechanism whereby DNA transfer may be effected, whether by suitable in vitro transformation techniques sich as calcium phosphate precipitation or calcium ion treatment, transduction by phage infection, conjugation. or other means. "Transform” as used herein simply denotes any process of causing DNA sequences to enter the host.
  • Recombinant host refers to cells that have been, are or will be transformed with DNA sequences prepared by recombinant techniques, and includes the cell originally transformed and, of course, cultures and progeny thereof.
  • Genomic library refers to a collection of DNA sequences which comprises fragments representing substantially the entire set of DNA sequences in a particular genome. These fragments may be simply a digest of chromosomal or genomic DNA or digest fragments cloned into host vectors and includes such materials whether or not transformed into recombinant host cells.
  • the genomic libraries herein may be, harbored in, for example, E. coli. or in ascomycetes.
  • the present invention provides a means for isolating selectable genes from filamentous ascomycetes, inserting them into convenient cloning vectors, and transforming filamentous ascomycete hosts.
  • the vectors of the invention provide a selectable gene, so as to enable homologous integration of the entire plasmid into the host genome, and, further to permit rescue of the plasmid DNA from the genome.
  • pHY201 comprises a coding sequence along with its control sequences derived from an Aspergillus strain, ligated to bacterial replication and marker sequences. This permits cloning of the vector DNA either in E. coli, or by integration into the genome of a filamentous ascomycete host.
  • vectors can, in principle, be employed as intermediates in the construction of expression vectors for desired coding sequences operable in ascomycete hosts by sequencing the selectable marker gene fragment cloned and isolated, restricting the sequence to eliminate all or part of the coding sequence, placing the desired coding sequence under the control of the promoter and terminating sequences associated with the marker gene, and inserting this package into a cloning vector, such as the intermediate here described, which contains an additional complete gene copy as marker.
  • a second general type of vector is a cosmid which comprises not only the bacterial sequences described above, along with a selectable marker for convenient manipulation, but also a cos site, along with a unique restriction site permitting the insertion of a genomic DNA fragment of the proper size derived from a filamentous ascomycete.
  • This type of intermediate is illustrated herein by pKBY2.
  • this second type of vector provides a general procedure for obtaining any desired gene from a filamentous ascomycete and cloning it.
  • genomic DNA from the selected filamentous ascomycete is prepared using standard procedures such as those described by Yelton. M., et al, Proc Natl Acad Sci (USA) (1984) 81:1470.
  • the genomic DNA is then digested with a restriction enzyme which recognizes frequently occurring sequences. The digestion is done at levels of enzyme and under conditions which will result in a random digestion of the genome. Suitable enzymes would be those which are capable of recognizing and cleaving sequences which occur randomly at intervals of approximately 100-500 bp.
  • the enzymes Mbol and Sau3A which recognize the sequence NGACTN (wherein N represents any one of the four possible nucleotides) are typical of appropriate restriction enzymes.
  • Other appropriate enzymes include MspI. HaeIII. HhaI, and AluI. none of which are overly fastidious as to their recognition sites.
  • Either the enzyme chosen must be compatible with the unique restriction site provided in the intermediate vector to accept the fragments, or linkers must be added to the fragments or to the genomic digest to provide this compatibility. Availability of the linker sequences and methods for obtaining this desired compatiblity using them are well established in the art.
  • the genomic fragments are then ligated into the unique restriction site provided in the intermediate vector.
  • the newly formed appropriately sized cosmids are then packaged into bacteriophage using standard techniques and the resulting phage library used to transduce a convenient host such as an ordinary E. coli strain to resistance to an antibiotic marker on the bacterial portion of the plasmid.
  • the resistant transformants can then be grown to obtain the desired quantities of DNA which can be then used to transform a desired filamentous ascomycete host.
  • the cosmid library obtained by use of the intermediate host cosmid vectors (exemplified below by pXBY2) and the derivative cosmids (exemplified below by those transforming GnI, GnII, and GnIII. or rescued as Cos yAI and Cos yAII) have at least two important utilities.
  • the first relates to placing genes from filamentous ascomycetes into non-indigenous environments to enable manipulation and modification of these genes: the other relates to utilizing the cloned genes as control sequences for the production and secretion of desired heterologous proteins.
  • Mutations in the gene encoding the enzyme would be capable of effecting such changes in such specificity of the resulting protein, however, there would be no way prevent mutagens applied directly to the industrial strain from producing. other unwanted effects. This might well prevent the industrial strain harboring the suitably modified enzyme from being useful in the desired conversion process.
  • industrial strains of microorganisms have been fine-tuned to optimize their growth and metabolic properties so as to obtain the desired amounts of products and suitable economic utilization of nutrients.
  • the industrial strain genome is digested as described above with a non-fastidious restriction enzyme, and ligated into an intermediate cosmid vector such as, for example, pKBY2, and transformed into a bacterial host, e.g., E. coli.
  • the resulting genomic library is then optionally and preferably selected for the approximately 40 kb fragment containing the coding sequence for the protein desired to be modified.
  • This representative of the library, cloned in, for example, E. coli is subjected to mutagens in this foreign host.
  • the DNA is recovered and transformed back into the industrial host. Because the plasmid DNA will integrate into the host cell genome at a position homologous to that of the unmutagenized coding sequence, the desired modified DNA is replaced into the industrial strain at'the same position as, and in substitution for, the unmodified DNA. It is thus assured that the modification has been selective for the protein of interest.
  • these and other vectors of the invention can provide a mechanism for genetic modification while the DNA sequence of interest is integrated into the genome of a substitute host strain. Modification under such conditions may be advantageous in providing a more analogous environment to that of the host wherein the modification will be more realistically related to the desired result. This is possible because the desired mutated sequences can be rescued from the substitute host, replicated in E. coli, and then retransformed into the desired ascomycete strain.
  • An additional utility of the gene isolating capacity of the cosmid vector sequences (again provided, although less efficiently by the first type of vector set forth herein) relates to the efficient production and secretion of heterologous peptides.
  • Filamentous ascomycetes are efficient and "natural" secretors of certain proteins.
  • the secreted protions because of the structure of the organisms, are transported into the medium rather than retained in the periplasmic space.
  • the secretion takes place through the mediation of suitable signal sequences associated with those proteins naturally secreted by the organisms. Accordingly, using the intermediate vectors of the invention, is possible to obtain complete coding sequences for the signal portions of these peptides and to ligate them to the coding sequences for the desired proteins.
  • the additional steps begin with obtaining a 35-40 kb fragment containing the gene for a secreted protein.
  • This is exemplified below with respect to the yA gene which encodes p-diphenol oxidase (laccase) an extracelluar enzyme which is conveniently detectable. Mutants lacking the enzyme have yellow spores. This enzyme provides such mutants with the ability to produce green spores, a readily detectable morphological change. Thus recipients of the vector containing the desired fragment can be easily identified. However, by analogous approaches involving mutant recipients deficient in the desired gene. any such gene may be located as part of a 35-40 kb insert.
  • the vector containing the yA gene is further studied by restriction and sequencing techniques to locate the gene more precisely. These techniques are conventional and are understood in the art.
  • One such technique involves random insertion of a transposon element. Briefly, the retrieved vector is treated with Tn5 according to the procedure of Brujin & Lupski, Gene (19 ) 27:131-149.
  • Tn5 is a transposon which inserts itself at random locations in a given substrate DNA sequence, destroying the functionality of any gene sequence into which it is inserted. The destruction of the functionality of the yA gene can easily be detected by the failure of mutant As p er Q illus nidulans hosts transformed with the plasmid to produce green spores, but rather production of yellow ones.
  • the coding sequence for the p-diphenol oxidase can be excised using standard recombinant techniques and replaced with a coding sequence for the desired heterologous protein, such as, for example, insulin or other hormones, lymphokines, growth factors, or other enzymic or structural proteins.
  • the coding sequence is placed in reading frame with the signal sequence retained in the cosmid.
  • the new cosmid, then containing the desired heterologous coding sequence is then transformed into a filamentous ascomycete host preferably an industrial strain, and cultured to produce and secrete the desired heterologous sequence.
  • the illustrated vector pHY201 is a derivative of a commonly available cloning vector. pBR329 and contains a copy of the trpC gene from A. nidulans.
  • the trpC gene encodes a trifunctional polypeptide which has glutamine amidotransferase (GAT). indole glycerol phosphate synthase (IGPS) and posphoribosylanthranilate isomerase (PRAI) activities.
  • GAT glutamine amidotransferase
  • IGPS indole glycerol phosphate synthase
  • PRAI posphoribosylanthranilate isomerase
  • the trpC gene was isolated from A. nidulans by construction of a ⁇ Charon 4 phage library using a XhoI digest of nuclear DNA from the strain. Selection of the desired phage.
  • ⁇ AntrpCl2 was made by lytic complementation of E. coli MC1066, a strain which is PRAI .
  • the selected phage containing the trpC gene was then cleaved with XhoI and the 4.1 kb segment cloned into pBR329 to give pHY201.
  • pHY201 was successful in transforming A. nidulans protoplasts to provide stable transformants, which contained the plasmid DNA integrated into the genome at the trpC , i.e.. the homologous, site.
  • the plasmid DNA could be recovered by isolating transformant genomic DNA, and digestion with Xhol.
  • Nuclear DNA from A. nidulans was isolated using a modification of the rapid isolation procedure developed for yeast by Davis, R.W., et al, Meth Enzymol (198 )65:404. Flasks containing 50 ml of minimal nitrate medium were inoculated with 5 x 10 7 condia from A. nidulans strain FGSC4, (obtained from the Fungal Genetic Stock Center, Humboldt State University Foundation, Arcata, CA) and grown at 37°C with agitation for 48-72 hr. The mycelium was harvested by filtration through Mira-Cloth.
  • the cells were rapidly suspended in 5 ml of 50 mM sodium EDTA, pH 8.5, 0.2% SDS containing 5 ⁇ l of diethyl oxydiformate and shaken for 1 min at room temperature.
  • the lysate was heated to 68°C for 15 min, cooled to room temperature, centrifuged for 15 min at 12,000 x g, and 4 ml of the supernatant was transferred to a new centrifuge tube.
  • the tube was placed on ice. 0.25 ml of 8.0 M potassium acetate, pH 4.2. was added, and the solutions were mixed thoroughly.
  • the tube was centrifuged at 25,000 x g at 4°C for 15 min. 3 ml of the supernatant was transferred to a fresh tube and nucleic acids were precipitated at room temperature by the addition of 3 ml of 2-propanol. The precipitate was collected by centrifugation and dissolved in 0.6 ml of TER [10 mM Tris-HC1, pH 7.6, 1 mM Na 2 EDTA, 10 ⁇ g/ml RNase A (previously heated to 90°C for 10 min)].
  • the solution was transferred to a 1.5 ml microcentrifuge tube and the DNA was precipitated at room temperature by the addition of 0.6 ml of 2-propanol and collected by centrifugation for 1 min. The pellet was finally dissolved in 50 ⁇ l of TER. Five ⁇ l of the DNA solution (1 ⁇ g DNA) was used for restriction endonuclease digestions and gel analysis.
  • the isolated DNA was digested with XhoI and cloned into ⁇ Charon 4 phage as desribed by Orr, W. C., et al, Proc Natl Acad Sci (1982) 79:5976. Selection of the desired phage was made by lytic complementation of E. coli strain MC1066 by the method of Davis. R. W.. et al, Manual for Genetic Engineering: Advanced Bacterial Genetics (1980) Cold Spring Harbor Laboratory, pp. 142-143. E. coli strain K12 MC1066 (Casadaban. M.
  • the selected phage was digested with XhoI and the 4.1 kb fragment ligated with Sail digested pBR329 (Covarrubias, L L., et al, Gene (1982) 17:79) and the litgation mixture transformed into E. coli K12 strain HB101 (Boyer. M W., et al. J Mol Biol (1969) 41:459).
  • Successful transformants as determined by Amp R Tet S were screened for the desired 8.2 kb plasmid.
  • the construction of the resulting pHY201 was confirmed by restriction analysis, and is diagrammed in Figure 1.
  • pHY201 as an intermediate vector for transforming A. nidulans was confirmed by transformation using this vector, and demonstration of integration of the plasmid DNA into the host cell chromosome. Transformation was conducted by preparation of protoplasts followed by treatment with the vector in the presence of a mediating agent, polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • Aspergillus protoplasts were prepared using a modification of the procedures of Peberdy, J. F., et al, Microbios Letters (1976) 3:7. Siliconized 1 liter flasks containing 400 ml of minimal medium plus 4 mM filter sterilized L-tryptophan were inoculated with 8 x 10 8 conidia of A. nidulans strain FGSC237, a strain which lacks GAT, IGPS and PRAI activities, obtainable from the Humboldt State University Foundation supra. The flasks were shaken at room temperature for 18 hours.
  • the mycelium was harvested by filtration through Mira-Cloth, washed with 0.6 M MgSO 4 and squeezed and blotted with paper towels to remove excess liquid.
  • the cells were suspended in filter sterilized osmotic medium (1.2 M MgSO 4 . 10 mM sodium phosphate, pH 5.8 ml/g mycelium) by vigorous vortexing, transferred to a 250 ml flask and placed on ice. Filter sterilized solutions of B-glucuronidase (0.2 ml/g mycelium) and Novozyme 234 (20 mg/ml in osmotic medium: 1 ml/g mycelium) were added and the cells were incubated on ice for 5 min.
  • osmotic medium 1.2 M MgSO 4 . 10 mM sodium phosphate, pH 5.8 ml/g mycelium
  • a filter sterilized solution of bovine serum albumin (12 mg/ml in osmotic medium/0.5 ml/g mycelium) was added and the cell suspension was shaken at 80 rpm at 30°C for 90 min.
  • the suspension was transferred to a centrifuge tube, overlayed with 10 ml of ST (0.6 M sorbitol, 100 mM Tris-HCl, pH 7.0) and centrifuged in a swinging bucket rotor at 4,000 x g at 4°C for 15 min.
  • Protoplasts at the buffer interface were removed using a bent Pasteur pipet and placed on ice.
  • the remaining ST was removed, the mycelial pellet was resuspended, fresh ST was added as before, and protoplasts were again banded by centrifugation.
  • the protoplasts were pooled, diluted with 2 volumes of STC (1.2 M sorbitol. 10 mM Tris-HC1, pH 7.5, 10 mM CaCl2) and pelleted by centrifugation at 4,000 x g at 4°C for 5 min. They were then washed twice by centrifugation with 10 ml of STC and resuspended in 1/1000 of the original culture volume of STC. Each 400 ml culture yielded 5-10 x 10 7 protoplasts. 20-30% of which were capable of regeneration when plated directly onto regeneration medium.
  • the transformation procedure used was a modification of that of Hinnen. A., et al, Proc Natl Acad Sci (USA) (1978) 75:1929.
  • DNA dissolved in 25 ⁇ l of STC, was mixed with 100 ⁇ l of protoplasts in a disposable plastic centrifuge tube and incubated at room temperature for 25 min. Then 0.2 ml of 60% polyethylene glycol 4000. 10 mM Tris-HC1, pH 7.5, 10 mM caCl 2 was added and the tube was agitated gently by hand. This was followed by a second addition of 0.2 ml and a third addition of 0.85 ml of the polyethylene glycol solution. with gentle mixing after each addition.
  • the protoplasts were incubated for 20 min at room temperature and pelleted at 8.000 x g at 4°C for 5 min. The supernatant was decanted and droplets of solution adhering to the tube were removed with a cottom swab.
  • the protoplasts were suspended in 2.5 ml of 0.5% yeast extract. 2.0% D-glucose, 1.2 M sorbitol and incubated at 37 C on a rotary shaker at 150 rpm for 2 hr. They were then pelleted at 8,000 x g at 4 C for 5 min. the supernatant was decanted and droplets of medium adhering to the tube were removed with a cotton swab.
  • the protoplasts were finally suspended in 0.15 ml of STC, diluted appropriately in the same buffer, spread onto medium containing 1.2 M sorbitol and 1.5% agar and incubated at 37°C.
  • the viability of the protoplasts following these treatments was 1-7%.
  • Plating the protoplasts in agar overlays had no effect on regeneration frequency.
  • DNA from host strain FGSC 237 whether undigested or digested with XhoI or SstI, fails to hybridize to kinased pBR329.
  • An apparently successful transformant HY201-3 gave similar results indicating either no integration or subsequent loss of integrated DNA in that case.
  • the remaining transformants yielded integrated DNA hybridizing to pBR329 probe and gave an altered hybridization pattern with respect to ⁇ AntrpCl2 probe as expected.
  • HY201-5 showed the integration of two tandem copies of HY201.
  • Mitotic stability was confirmed by growing colonies from single conidia on at least 50 isolates onto selective and non-selective media. All of the colonies remained trp + . Meiotic stability was verified by allowing transformants to self under non-selective conditions and verification that at least 50 colonies derived from single ascospores were trp + . All colonies obtained from HY201-3 were trp + , HY201-6 and HY201-1 resulted in 2% and 12% trpC segregants respectively.
  • This paragraph sets forth the preparation of the host cosmid pKBY2.
  • This cosmid was designed to be useful in creating a doubly selective system for obtaining a complete genomic DNA library from filamentous ascomycetes which thus permits the cloning of any desired gene from the donor chromosomal structures.
  • the resulting cloned genes are contained in cosmid vectors which are useful for transforming either bacterial or ascomycetes hosts. Accordingly, they are useful as substrate materials which can be transformed into substitute hosts for genetic n modification, followed by rescue, then transformation into a target host where they are able to mediate the replacement of a desired sequence by a modified one in this host. They are also useful as sources for signal and control sequences which can be ligated to coding sequences for desired proteins. The resulting fusions may then be used to transform filamentous ascomycetes in order to effect the production and secretion of large amounts of the desired heterologous protein.
  • a plasmid containing the cos site, pJB8 (Ish-Horowicz, D., et al, Nucleic Acids Res (1981) 9:2989-2998) was digested with HindIII and SalI and the 2.1 kb fragment containing the cos site isolated. This fragment was ligated to a HindIII/SalI digest of pBR329 and the ligation mixture transformed into E. coli HB101 to Amp R Tet S . The construction of the desired plasmid pKBYO.l was confirmed by restriction analysis.
  • pKBYO.1 was digested with SalI, and ligated with the 4.1 kb SalI fragment containing the A. nidulans trpC gene prepared as set forth in paragraph C.I. This mixture was transformed into E. coli HB101 to AmpR. and the construction of the desired pKBYO.2 confirmed by restriction.
  • pKBYO.2 was further modified by ligating a BamHI linker obtained from Bethesda Research Laboratories into the NruI site located in the pBR329-derived portion to produce pKBYl.
  • pKBY1 was digested with XbaI to liberate a 1.5 kb fragment, which fragment was replaced by a corresponding modified Xbal fragment from which the internal BamHI site had been removed by sodium bisulfite mutagenesis (Shortle, D., et al, Proc Natl Acad Sci (USA) (1978) 75:2170).
  • This ligation mixture was used to transform from E. coli HB101 to Amp R .
  • the transformation frequency was similar to that of pHY201 (supra).
  • pKBY2 The construction of pKBY2 was confirmed by restriction analysis to contain the ampicillin and chloramphenicol resistance markers and replication site of pBR329, the modified trpC sequences, the cos site and a unique (BamHI) restriction site adjacent the trpC marker suitable to receive a donor genomic fragment. Fragments produced by digestion of, for example, genomic DNA by BamHI, BglII, MboI or Sau3A can be used directly as donor fragments into this site. pKBY2 is diagrammed in Figure 3.
  • pKBY2 was then used as a host vector to obtain a ⁇ phage library of filamentous ascomycetes genes.
  • the gene-containing cosmids were thus selectable through two screens--only ligation products which incorporated the proper size genomic fragments are incorporated into phage so as to become infective against E. coli. and only ligation products containing the trpC marker were successful in providing the infected bacteria with metabolic systems needed to grow in the absence of trptophan.
  • Nuclear DNA was isolated from Aspergillus nidulans strain FGSC4 (Glasgow Wild Type) by the method of Davis, et al described in paragraph C.l. Five 40 ⁇ g samples of isolated DNA were treated with varying amounts of MboI to yield digestion products ranging in size from 0.5-70 kb. The reaction mixtures were combined and subjected to sucrose density gradient ultracentrifugation as described by Maniatis, el al. Cell (1978) 15:687-701 to obtain fractions containing 30-50 kb fragments as verified by agarose gel electrophoresis.
  • the 30-50 kb fragments were precipitated by addition of 2.5 volumes of 95% ethanol, collected by centrifugation, washed twice with 70% ethanol, dried and resuspended in TC buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA). The DNA was precipitated and washed and resuspended in TC buffer at a concentration of 400 ⁇ g/ml.
  • the isolated cosmids were found to have an average size of cloned fragment of 35-40 kb as judged by electrophoretic analysis of EcoRI digestion products; each contained a different insert. Thus about 800 cosmids from the library are equivalent to the size of the A. nidulans genome.
  • transformants were designated Gnl, GnII, and GnIII, and were purified by two cycles of single spore isolation on medium lacking trytophan before subjecting them to further analysis. These transformants were characterized as set forth in D.3.b, and the cosmid DNA rescued as set forth in D.3.c.
  • XhoI digestion gave, in all cases, a single large > 10 kb fragment that hybridized to pBR329, which was smaller in the DNA from GnIII than in DNA from GnI and GnII.
  • ⁇ AntrpCl2 DNA hybridized with the expected XhoI fragments from the chromosome as well as with the same large fragment as hybridized to pBR329. All of the spots were of approximately such intensity, as to be consistent with one additional copy of the trpC gene per cell.
  • the presence of an unaltered 4.1 kb XhoI fragment in the transformants shows that the transforming DNA had not integrated into the resident trpC gene.
  • a suspension of spores from the truC + colonies obtained from transformation of A. nidulans FGSC237 with the cosmid library DNA of fD.2 were selected for abaA + .
  • the pabaA2 allele reverts at a 7 + frequency of ⁇ 4 x 10 7 .
  • Four ap baA + , yA2: ttpC + colonies were selected, purified by two cycles of single spore isolation and total DNA was prepared. Analysis of gel blots showed that each isolate contained pKBY2 DNA sequences and an unaltered, 4.1 kb Xhol fragment containing the trpC801 allele, as was the case with the green-spored transformants.
  • ATCC American Type Culture Collection, Rockville, MD,USA
  • ATCC accession no. 39899 ATCC accession no. 39899
  • pKBY2 in E.Coli HB101
  • ATCC accession no. 39898 ATCC accession no. 39898. This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure and the Regulations thereunder (Budapest Treaty). ATCC 39898 is now fully available without restrictions and ATCC 39899 is available under EPC Rule 28.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP85307648A 1984-10-24 1985-10-23 Vektoren zur Transformation von Ascomyceten Withdrawn EP0191221A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66423084A 1984-10-24 1984-10-24
US664230 1984-10-24

Publications (1)

Publication Number Publication Date
EP0191221A1 true EP0191221A1 (de) 1986-08-20

Family

ID=24665144

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85307648A Withdrawn EP0191221A1 (de) 1984-10-24 1985-10-23 Vektoren zur Transformation von Ascomyceten

Country Status (1)

Country Link
EP (1) EP0191221A1 (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001969A1 (en) * 1987-09-04 1989-03-09 Novo-Nordisk A/S Process for the production of protein products in aspergillus and promoters for use in aspergillus
US4885249A (en) * 1984-12-05 1989-12-05 Allelix, Inc. Aspergillus niger transformation system
US4885252A (en) * 1987-09-08 1989-12-05 Eli Lilly And Company Recombinant DNA expression vectors and DNA compounds that encode isopenicillin N synthetase from aspergillus nidulans
AU606033B2 (en) * 1985-04-15 1991-01-31 Dsm Ip Assets B.V. Promotors of filamentous fungi and use thereof
US5447862A (en) * 1987-02-04 1995-09-05 Ciba-Geigy Corporation Pectin lyase genes of aspergillus niger
US5536661A (en) * 1987-03-10 1996-07-16 Novo Nordisk A/S Process for the production of protein products in aspergillus
WO1998033925A1 (en) * 1997-02-03 1998-08-06 Yale University Glutrnagln amidotransferase - a novel essential translational component
US5965384A (en) * 1986-03-17 1999-10-12 Novo Nordisk A/S Methods for producing Humicola lipases in aspergillus
US6180361B1 (en) 1987-03-04 2001-01-30 Eli Lilly And Company Recombinant DNA expression vectors and DNA compounds that encode deacetoxycephalosporin C synthetase and deacetylcephalosporin C synthetase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 112, no. 1, 1983 (New York) D.J. BALLANCE et al. "Transformation of Aspergillus nidulans by the Orotidine-5'-Phosphate Decarboxylase Gene of Neurospora crassa" pages 284-289 *
GENE, vol. 26, 1983, (AMSTERDAM) J. TILBURN et al. "Transformation by integration in Aspergillus nidulans" pages 205-221 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885249A (en) * 1984-12-05 1989-12-05 Allelix, Inc. Aspergillus niger transformation system
AU606033B2 (en) * 1985-04-15 1991-01-31 Dsm Ip Assets B.V. Promotors of filamentous fungi and use thereof
US5863759A (en) * 1986-03-17 1999-01-26 Novo Nordisk A/S Process for the production of protein products in aspergillus
US5965384A (en) * 1986-03-17 1999-10-12 Novo Nordisk A/S Methods for producing Humicola lipases in aspergillus
US7517668B1 (en) 1986-03-17 2009-04-14 Novozymes A/S Process for the production of protein products in aspergillus
US5447862A (en) * 1987-02-04 1995-09-05 Ciba-Geigy Corporation Pectin lyase genes of aspergillus niger
US6180361B1 (en) 1987-03-04 2001-01-30 Eli Lilly And Company Recombinant DNA expression vectors and DNA compounds that encode deacetoxycephalosporin C synthetase and deacetylcephalosporin C synthetase
US5536661A (en) * 1987-03-10 1996-07-16 Novo Nordisk A/S Process for the production of protein products in aspergillus
WO1989001969A1 (en) * 1987-09-04 1989-03-09 Novo-Nordisk A/S Process for the production of protein products in aspergillus and promoters for use in aspergillus
US4885252A (en) * 1987-09-08 1989-12-05 Eli Lilly And Company Recombinant DNA expression vectors and DNA compounds that encode isopenicillin N synthetase from aspergillus nidulans
WO1998033925A1 (en) * 1997-02-03 1998-08-06 Yale University Glutrnagln amidotransferase - a novel essential translational component

Similar Documents

Publication Publication Date Title
US4816405A (en) Vectors for transformation by ascomycetes
JP4307563B2 (ja) 糸状菌、特にアスペルギルス属に属する糸状菌のアグロバクテリウム媒介性形質転換
Manstein et al. Gene replacement in Dictyostelium: generation of myosin null mutants.
JP3833725B2 (ja) 選択マーカー遺伝子を含まない組換え体株、その作製方法及びその株の使用
JP2669457B2 (ja) 工業微生物種中の分子クローニングおよび発現
CA2168037C (en) Transformation systems for the yeast candida utilis and the expression of heterologous genes therewith
Hamada et al. Transformation of Botrytis cinerea with the hygromycin B resistance gene, hph
JPS62104585A (ja) ピチア属酵母の部位選択的ゲノム修飾
WO2001007633A1 (en) Novel system for the sequential, directional cloning of multiple dna sequences
FI105484B (fi) Pektiinilyaasin ilmentämisjärjestelmää koodittava yhdistelmä-DNA-molekyyli
Walz et al. Transformation of Sordaria macrospora to hygromycin B resistance: characterization of transformants by electrophoretic karyotyping and tetrad analysis
EP0191221A1 (de) Vektoren zur Transformation von Ascomyceten
EP0540074A1 (de) Klonierung und Sequenzierung der chromosomalen DNS-Region aus Bacillus subtilis, die den für den Multienzym-Komplex Surfactin-Synthetase kodierenden SRFA Operon enthält
JP2002515252A (ja) 糸状菌変異体細胞においてポリペプチドを生産するための方法
US6436643B1 (en) Process for site-directed integration of multiple copies of a gene in a mould
US20090105088A1 (en) Mutant bank
Burmester Transformation of the mycoparasite Parasitella simplex to neomycin resistance
US7001751B1 (en) PyrF gene and the utilization thereof
HU197351B (en) Process for preparing polypeptide from genetically codeable aminoacids
US4959327A (en) Vectors and method of penicillium chrysogenum transformation
JPH06343471A (ja) ポリペプチドの製造方法
Turner et al. Utilization of the Aspergillus nidulans pyrG gene as a selectable marker for transformation and electroporation of Neurospora crassa
JP2004538004A (ja) メチロトローフ酵母のｒＤＮＡ部位への異種ＤＮＡ配列の部位特異的組み込みのためのベクター
JPH01157393A (ja) 酵母における安定なゲノム組込みおよび外来コーディング配列の発現
EP0815241B1 (de) Identifikation und klonierung eines mobilen aspergillus transposons

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19870130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19890503

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YELTON, M. MELANIE

Inventor name: HAMER, JOHN E.

Inventor name: TIMBERLAKE, WILLIAM E.